Adial Pharmaceuticals Shares Are Trading Higher After the Company Announced It Received FDA Feedback for Its Vitro Bridging Strategy of AD04 and Will Proceed to Manufacture Clinical Supplies for Its Upcoming Phase 3 Clinical Trial.

BenzingaFeb 25 09:05 ET

Express News | Adial Pharmaceuticals Receives Positive Response From FDA Meeting Regarding Proposed in Vitro Bridging Strategy for Ad04

ReutersFeb 25 09:00 ET

Adial Pharmaceuticals Receives Positive Response From FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

GlobeNewswireFeb 25 09:00 ET

EXCLUSIVE: After FDA Response, Adial Starts Manufacturing Clinical Supplies For Upcoming Phase 3 Program Of Lead Candidate For Alcohol Use Disorder

BenzingaFeb 25 08:30 ET

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

GlobeNewswireFeb 12 09:00 ET

Express News | EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'New Patent Expands Patent Estate Covering Adial's Unique Molecular Genetic Approach to Diagnosing and Potentially Treating Alcohol and Drug Dependence'

BenzingaFeb 12 08:30 ET

Express News | EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga Co. Awarded New U.S Patent Covering Genotype-Specific Treatment Of Opioid -Related Disorders

BenzingaFeb 12 08:30 ET

EXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

BenzingaFeb 12 08:30 ET

EXCLUSIVE: Adial Pharmaceuticals Reveals Positive Pharmacokinetics Study Results Of AD04 For Alcohol Use Disorder

BenzingaJan 29 08:31 ET

Express News | EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Safety and Tolerability Consistent With Ondansetron's Extensive Human Use Experience'

BenzingaJan 29 08:30 ET

Express News | EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Adial's Formulation Exhibited Predictable Bioavailability Relative to the Reference Standard; Near-micro Doses Exhibited Dose Proportionality in Pharmacokinetic Exposure, and No Food Effect'

BenzingaJan 29 08:30 ET

Express News | EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Completion Enables the End-of-Phase 2 (EOP2) Interaction With the FDA on the Design of the Phase 3 Program and Is Expected to Facilitate Ongoing Partnership Discussions'

BenzingaJan 29 08:30 ET

Adial Pharmaceuticals Focuses on Strategic Growth Initiatives

TipRanksJan 13 09:02 ET

Adial Pharmaceuticals' New Purchase Agreement With Alumni Capital

TipRanksDec 18, 2024 17:34 ET

Express News | Adial Pharmaceuticals Inc - Can Sell up to $10 Million in Shares

ReutersDec 18, 2024 17:02 ET

Express News | Adial Pharmaceuticals Inc - on Dec 13, Enters Purchase Agreement With Alumni Capital

ReutersDec 18, 2024 17:02 ET

Adial Pharmaceuticals Extends CEO Cary Claiborne's Tenure

TipRanksDec 6, 2024 17:30 ET

EXCLUSIVE: Adial Pharmaceuticals' Lead Drug Secures Key US Patent For Alcohol Dependence Based on Expanded Genotype Combinations

BenzingaDec 3, 2024 08:00 ET

Express News | EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga Co. Granted Key U.S. Patent For The Treatment Of Alcohol And Drug Dependence Based On Expanded Genotype Combinations

BenzingaDec 3, 2024 08:00 ET

Adial Pharmaceuticals (ADIL) Upgraded to Buy: Here's What You Should Know

Yahoo FinanceNov 25, 2024 12:00 ET